Hey there,
We just published a new blog post on the sources Elicit’s Research Agent can draw on beyond research papers.
Take a question like: is TREM2 a promising target for Alzheimer’s disease? Papers tell you part of the story, but the human genetic evidence is in Open Targets, the competitive landscape is in patent filings, and potency data is in ChEMBL. Answering well means finding each piece and putting it all together.
The post covers five of those sources, what each one adds, and the kinds of questions that trigger it:
- Patents: who owns a composition or method, and how broad their claims are
- Target–disease evidence: structured genetic and clinical support linking genes to diseases
- Cancer dependencies: whether a gene is a selective vulnerability or something every cell needs
-
Safety reports: what’s been reported for marketed drugs and devices, and whether a signal is growing
- Drug chemistry: standardized potency measurements like IC50, Ki, and Kd
Read the full post here: Where Elicit looks beyond research papers
Happy reading,